Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aseem Anand

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical Chemistry|February 24, 2009
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survivalPauliina Helo, Angel M Cronin, Daniel C Danila, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerDana Rathkopf, Glenn Liu, Michael A Carducci, et al.
Nature Medicine|November 27, 2019
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variantsPedram Razavi, Bob T Li, David N Brown, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical Chemistry|February 24, 2009
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survivalPauliina Helo, Angel M Cronin, Daniel C Danila, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerDana Rathkopf, Glenn Liu, Michael A Carducci, et al.
Nature Medicine|November 27, 2019
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variantsPedram Razavi, Bob T Li, David N Brown, et al.
Pageof 4